The Q4 2025 upgrade promises to increase Ethereum's data capacity eightfold, adding tougher defenses, and new developer tools ...
The DESTINY-Breast05 trial included patients with HER2-positive primary breast cancer who were at high risk of recurrence and had residual invasive disease in breast or axillary lymph nodes following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback